Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Canada Approves Valeant's Jublia for Fungi Infections

October 3, 2013 10:42 am | News | Comments

Valeant Pharmaceuticals International Inc. announced that the New Drug Submission for Jublia has been approved from the Canadian regulatory authority, Health Canada, for the treatment of mild to moderate onychomycosis, a common and destructive nail infection caused predominantly by dermatophyte fungi.


New Drug Effectively Lowers Cholesterol

October 3, 2013 10:36 am | News | Comments

Alnylam Pharmaceuticals Inc., an RNAi therapeutics company, announced the pubication of study results from a Phase 1 trial with ALN-PCS, a systemically administered RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia.


Janssen, CureVac Collaborate on Influenza Vaccine

October 3, 2013 10:24 am | News | Comments

CureVac announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals Inc. Under the agreement CureVac and a Janssen Pharmaceutical Companies' affiliate will develop of an influenza vaccine based on CureVac's RNActive technology.


Ramucirumab Trial Shows Improved OS in Gastric Cancer

October 3, 2013 10:15 am | News | Comments

Eli Lilly and Co. announced that results from the Phase 3 REGARD trial of ramucirumab as a single agent in patients with advanced gastric cancer who have had disease progression after initial chemotherapy. The drug achieved a median overall survival of 5.2 months compared to 3.8 months for patients on the placebo arm.


Erectile Dysfunction Drugs May Prevent Colon Cancer

October 3, 2013 10:01 am | News | Comments

Erectile dysfunction drugs may be able to help prevent or even treat colon cancer, researchers say. They are studying three drugs, including Viagra, that appear to protect the lining of the colon from inflammation and other damage resulting from the relentless onslaught of food, drink and bacteria that we consume.


Prothena Offering 5.9 Million Shares

October 3, 2013 8:30 am | News | Comments

Prothena Corp. PLC is planning an offering of 5.9 million shares that could raise about $130 million. The drug developer will share some proceeds with one of its shareholders, Janssen Pharmaceutical. Ireland's Prothena said that it will contribute 3.5 million shares and Janssen, a subsidiary of Johnson & Johnson, will add about 2.4 million.


Zogenix's Pain Drug Moves Closer to Approval

October 2, 2013 2:10 pm | News | Comments

The FDA has not found any deficiencies in Zogenix's marketing application, and the company has reached an agreement with the agency on the safety label for the drug. So will Zogenix's long-delayed pain drug Zohydro finally get approved by the FDA despite a negative panel review in 2012? Find out...


Optivia Gets $1.8 M to Build CNS Drug Discovery Tools

October 2, 2013 2:02 pm | News | Comments

Optivia Biotechnology Inc. has received a $1.8 million federal grant to advance the understanding of central nervous system (CNS) physiology. So how will these new tools help to design new CNS drugs, identify new drug targets and manage potential drug side effects? Find out...


FDA OKs Stem Cell Trial for Spinal Cord Injuries

October 2, 2013 1:47 pm | News | Comments

The U.S. Food and Drug Administration (FDA) has authorized the StemCells Inc.'s application for clinical testing of the company's HuCNS-SC human neural stem cells as a treatment for spinal cord injury. How successful has its international trials been so far? Find out...


New Target to Fight HIV Infection Identified

October 2, 2013 1:40 pm | News | Comments

A mutant of an immune cell protein called adhesion and degranulation-promoting adaptor protein (ADAP) is able to block infection by HIV-1, according to a new paper published in Biomed Central. Could this discovery lead to new ways to combat HIV?


$3 Drug Reduces Heart Attack Damage

October 2, 2013 1:34 pm | News | Comments

Early treatment of heart attack patients with an inexpensive beta-blocker drug called metoprolol, while in transit to the hospital, can significantly reduce damage to the heart during a myocardial infarction. Could this help lower the cost of healthcare in general? Find out...


Compound That Reduces Risk of Stroke Identified

October 2, 2013 1:25 pm | News | Comments

Johns Hopkins researchers have identified a chemical compound that reduces the risk of dangerous, potentially stroke-causing blood vessel spasms that often occur after the rupture of a bulging vessel in the brain. Could this lead to a drug to prevent stroke after the rupture of an aneurysm? Find out...


Quantitative Phase Imaging in a Silicon Environment

October 2, 2013 1:12 pm | News | Comments

A team of scientists from The University of Texas at Arlington and the Massachusetts Institute of Technology (MIT) has figured out how to quantitatively observe cellular processes taking place on lab-on-a-chip devices in a silicon environment. So how could this new technology be used in drug development? Find out...


Hypertension Drug as Chemo Booster?

October 2, 2013 10:12 am | News | Comments

Common blood-pressure drugs could potentially improve the effectiveness of cancer chemotherapy if the outcomes seen in animal experiments hold true in people, according to researchers. By opening up collapsed blood vessels in solid tumors, the angiotensin inhibitor losartan improved the delivery of chemotherapy drugs and oxygen by increasing blood flow.


FDA Approves Takeda-Lundbeck Drug for Depression

October 2, 2013 10:05 am | News | Comments

Takeda Pharmaceutical Co. Ltd. and H. Lundbeck A/S jointly announced that the FDA has approved Brintellix for the treatment of adults with major depressive disorder (MDD), a debilitating mental health illness affecting approximately 14 million adult Americans in a given year.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.